Objective: Dual bronchodilation with long-acting muscarinic antagonist and long-acting β2-agonist combinations are available worldwide in COPD patients. However, the choice of agents remains under debate. We hypothesized that switching devices between dry powder and soft mist inhalers without a wash-out period to mimic clinical practice would improve clinical symptoms and lung function. The aim of this study was to examine the effects of switching between once-daily glycopyrronium/indacaterol (GLY/IND) or umeclidinium/vilanterol (UMEC/VI), dry powder inhalers, and tiotropium/olodaterol (TIO/OLO), a soft mist inhaler, in COPD patients. Methods: This was a prospective, open-label, 8-week, observational study with follow-up. Subjects included 57 COPD patients, who attended outpatient clinics at Shizuoka General Hospital for routine check-ups between February and December 2015, receiving GLY/IND (50/110 μg) or UMEC/VI (62.5/25 μg). After an 8-week run-in period, medications were switched to TIO/OLO (5/5 μg). Study outcomes included patient’s global rating (PGR), modified MRC (mMRC), COPD assessment test (CAT), and spirometric and forced oscillatory parameters after 8 weeks. PGR used in this study was a 7-point scale ranging from 1 to 7, with 4 in the middle. Patients who consented to switch from TIO/OLO to GLY/IND or UMEC/VI were followed-up thereafter. Results: In total, 53 patients completed the study (mean age, 75 years; 48 males and 5 females; GOLD 1/2/3/4 = 19/27/6/1; mMRC 0/1/2/3/4 = 14/22/12/4/1; UMEC/VI 26, GLY/IND 27). PGR, mMRC, and CAT improved in 20 (38%), 9 (17%), and 15 patients (28%), respectively. Respiratory system resistance at 5 Hz (R5), 20 Hz (R20), and the difference between R5 and R20 (R5 - R20) significantly improved. In a follow-up of 16 patients after switching from TIO/OLO to UMEC/VI (9) or GLY/IND (7), PGR, mMRC, and CAT improved in 5 (31%), 3 (12%), and 4 patients (25%), respectively, and R20 significantly improved (p = 0.011). Conclusions: Switching dual bronchodilators between dry powder and soft mist inhalers improves symptoms and airway narrowing in some COPD patients.
References
[1]
Global Initiative for Chronic Obstructive Lung Disease (2019) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. https://goldcopd.org
[2]
Calzetta, L., Rogliani, P., Matera, M.G. and Cazzola, M. (2016) A Systematic Review with Meta-Analysis of Dual Bronchodilation with LAMA/LABA for the Treatment of Stable COPD. Chest, 149, 1181-1196. https://doi.org/10.1016/j.chest.2016.02.646
[3]
Bestall, J.C., Paul, E.A., Garrod, R., Garnham, R., Jones, P.W. and Wedzicha, J.A. (1999) Usefulness of the Medical Research Council (MRC) Dyspnoea Scale as a Measure of Disability in Patients with Chronic Obstructive Pulmonary Disease. Thorax, 54, 581-586. https://doi.org/10.1136/thx.54.7.581
[4]
Jones, P.W., Harding, G., Berry, P., Wiklund, I., Chen, W.H. and Kline, L.N. (2009) Development and First Validation of the COPD Assessment Test. European Respiratory Journal, 34, 648-654. https://doi.org/10.1183/09031936.00102509
[5]
Oostveen, E., MacLeod, D., Lorino, H., Farre, R., Hantos, Z., Desager, K., et al. (2003) The Forced Oscillation Technique in Clinical Practice: Methodology, Recommendations and Future Developments. European Respiratory Journal, 22, 1026-1041. https://doi.org/10.1183/09031936.03.00089403
[6]
Shirai, T. and Kurosawa, H. (2016) Clinical Application of the Forced Oscillation Technique. Internal Medicine, 55, 559-566. https://doi.org/10.2169/internalmedicine.55.5876
[7]
Miller, M.R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., et al. (2005) Standardisation of Spirometry. European Respiratory Journal, 26, 319-338. https://doi.org/10.1183/09031936.05.00034805
[8]
The Committee of Pulmonary Physiology, Japanese Respiratory Society (2004) Guidelines for pulmonary function tests. Spirometry, Flow-Volume Curve, Diffusing Capacity of the Lung. Japanese Respiratory Society, Tokyo.
[9]
Kanda, Y. (2013) Investigation of the Freely Available Easy-to-Use Software ‘EZR’ for Medical Statistics. Bone Marrow Transplantation, 48, 452-458. https://doi.org/10.1038/bmt.2012.244
[10]
Feldman, G.J., Sousa, A.R., Lipson, D.A., Tombs, L., Barnes, N., Riley, J.H., et al. (2017) Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. Advances in Therapy, 34, 2518-2533. https://doi.org/10.1007/s12325-017-0626-4
